Merck & Co., Inc. (ETR: 6MK)
Germany
· Delayed Price · Currency is EUR
95.00
-0.50 (-0.52%)
Dec 20, 2024, 5:35 PM CET
Merck & Co. Revenue
Merck & Co. had revenue of $16.66B USD in the quarter ending September 30, 2024, with 4.35% growth. This brings the company's revenue in the last twelve months to $63.17B, up 6.51% year-over-year. In the year 2023, Merck & Co. had annual revenue of $60.12B with 1.40% growth.
Revenue (ttm)
$63.17B
Revenue Growth
+6.51%
P/S Ratio
n/a
Revenue / Employee
$877.42K
Employees
72,000
Market Cap
238.11B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
Dec 31, 2019 | 39.12B | -3.17B | -7.50% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionMerck & Co. News
- 1 day ago - Merck & Co Inc (MRK) Secures Global License for Innovative Cancer Therapy LM-299 - GuruFocus
- 1 day ago - Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody - Wallstreet:Online
- 1 day ago - Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody - Business Wire
- 2 days ago - Merck's Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials - Benzinga
- 2 days ago - Stock Of The Day: Where Does The Merck Downtrend End? - Benzinga
- 2 days ago - Stock Of The Day: Where Does The Merck Downtrend End? - Benzinga
- 2 days ago - Personalis stock rallies 25% amid $50M Merck investment - Seeking Alpha
- 2 days ago - Merck: Healthcare Pharma Giant: 3.2% Yield, 9.3% 5-Year Dividend Growth, Buy Time - Seeking Alpha